Life Sciences Archive » February, 2013

Life Sciences - February, 2013

243 articles

• Top Plaintiffs Firms Say Amgen No License To Print Money
• Takeda Failed To Warn Of Actos Cancer Risk, Jury Hears
• Amgen Dissents Put Fraud On The Market On Thin Ice
• Merck Criticizes FTC's Proposed Pay-For-Delay Rule
• Icahn Gains Two Herbalife Directors In Feud With Ackman
• Bayer Budgeted $1.6B For Yaz, Yasmin Suits
• Warner Chilcott Says Contracts Bar Retailers' Doryx Suit
• Texas Appeals Court Nixes $10M Award Against Fen-Phen Atty
• DePuy Should Pay $23M Over Faulty Hip Implant, Jury Told
• J&J Hit With $7.8M Punitive Award Over Vaginal Mesh Product
• CMS Escapes DME Bidding Dispute Despite Judge's Rebuke
• Skadden Reps Mylan In $1.6B Buy Of Indian Generics Maker
• PerkinElmer — A Sign Of What's To Come For Diagnostics
• 6 Areas Often Underestimated In Law Firm Mergers
• DePuy Plaintiff's Metal Hip Didn't Need Replacing, Jury Hears
• Amgen's High Court Defeat Leaves Defense Bar Reeling
• 1st Thoughts On Supreme Court's Amgen Ruling
• FDA Issues Pediatric Drug Labeling Guidelines
• GSK Not Immune To Drug-Discount Antitrust Suit, Clinic Says
• Employers Ask Supreme Court To Find DOMA Unconstitutional
• Alcon Accused Of Selling Big Bottles To Boost Profits
• How Inter Partes Review Impacts Hatch-Waxman Exclusivity
• High Court Rebuffs Amgen, Lowering Bar For Investor Suits
• Pfizer Gets New Trial After $39M Trade Secrets Verdict
• NJ Jury Mulls Punitive Damages In J&J Vaginal Mesh Trial
• Vaginal Mesh Injuries Strike A Chord With Jurors
• Judge Axes $500M FCA Suit Over Public Info-Based Claims
• Surgeon Says DePuy Hip Implant Was Thoroughly Tested
• Device Industry Vows To 'Double Down' On Tax Repeal
• FDA Sets Child Safety Rule After Death In Amgen Trial
• FDA Warns Supplement Co. Over Facebook 'Like'
• Endurance Doesn't Owe Defense In Pollution Control Suit
• Quigley To Make Another Bid For Plan Confirmation In June
• Reed Smith Says Howdy To Houston With 12-Partner Office
• Daubert-Style Gatekeeping In Calif.? Not Quite
• Eli Lilly Can't Escape Class Action Over Cymbalta Labeling
• Shine Might Be Off Alt Fee Arrangements, GC Survey Shows
• GCs Brace For More Whistleblower Suits
• In-House Teams Expand To Keep Pace With More Suits, Probes
• BioClinica Shareholders Can't Stop $123M PE Takeover Bid
• GCs Rate Fixed Fees Best Bang For Their Buck
• DePuy Hip Failure Due To Incorrect Angle, Jury Hears
• Patheon Can't Duck JV Partner's Suit Over $255M Acquisition
• Enema Maker Claims Rival Defamed Its Product To VA
• FDA Eyes New Rule For Foreign Clinical Data On Devices
• Medicare Could Save $14M With Drug Price Controls: Report
• DePuy Knee Joint Part Recalled Over Fracture Risk
• Pharma Execs Can't Duck Prosecutors With Off-Label Ruling
• Dynavax's Hep B Vaccine Doesn't Pass Muster With FDA
• High Court Won't Weigh UnitedHealth ERISA Preemption Case
• J&J Hit With $3.35M Verdict In Vaginal Mesh Bellwether
• FDA Refers Reckitt To FTC For Hindering Generic Suboxone
• Royalty Pharma Lobs $6.6B Takeover Bid At Elan
• Pharma Cos., Scan Your Drugs For Proper Barcodes
• Firms End Battle Royal Over $4M Pfizer Settlement Fees
• Vinson & Elkins Won't Be Booted From Galderma IP Suit
• Compounding Group Open To Oversight Talks With FDA
• Warner Chilcott Falsely Promoted Drugs, FCA Suit Says
• 6th Circ. Resurrects Vitamin C Labeling Suit Against P&G
• DePuy Designer Blames Some Surgeons For Hip Failures
• UK Court Sides With Genentech In Eye-Treatment Patent Suit
• J&J Reveals Gov't Probes Of Hip Implant, Surgical Mesh
• Novartis Sues To Block Generic Reclast, Zometa Drugs
• Dialysis Industry Continues To See Robust PE Activity
• FDA Chief Warns Generics Industry On Safety Lapses
• Merck, Pa. Reach $8.25M Settlement Over Vioxx Disclosures
• A Food Industry Issue Menu For 2013: Part 2
• Calif. Lawmaker Floats Genetic Privacy Bill Again
• Pharma Cos. Rip FTC's Bid To Bar Pay-For-Delay Deals
• Ky. Adds To GSK's Avandia Woes With 2nd State Suit
• LabCorp Ducks Some Stanford Claims In Prenatal Test IP Row
• Teva Slams Antitrust Claims In Azilect Patent Row
• Leibowitz Tells Law360 He's Leaving FTC In Good Shape
• Medical Device Co. Sanctioned For Iran Exports
• US Wants Voice In Supreme Court Generic-Drug Showdown
• DePuy's Metal Hip Implant Wasn't Poisonous, Expert Says
• German Co. Beats AntiCancer's Tumor Imaging Patent Suit
• Travelers Sues To Dodge Coverage In Medical Device IP Row
• Successful Life Science Collaborations Require Flexibility
• Maryland AG Hits GSK With Avandia False Claims Suit
• 3rd Circ. Reinstates Former Teleflex Exec's Age Bias Case
• Medicare Heavily Overpaid For Infusion Drugs, Report Says
• FDA Warns Against Post-Surgery Use Of Codeine In Kids
• Complete Genomics Says Its Probes Differ From Illumina's
• Teva Settles Gilead's HIV Drug Patent Suit As Trial Looms
• Hogan Lovells Snags Drug Regulatory Pro From Sidley Austin
• Ranbaxy Attacks Recall Demand In Glass Particles Action
• Diagnostics Co. Hycor Unloads Unit In Sale To PE Group
• How EPA Will Clean Things Up In 2013
• Herbalife Confirms SEC Probe Into Finances
• DePuy Reps Didn't Report Hip Implant Complaints, Jury Hears
• Pfizer Asks Ala. Top Court To Undo Generics Liability Ruling
• FDA Says Device Makers Must Provide Pediatric Data
• Pillsbury Adds Ex-Crowell & Moring Health Partner In DC
• Look Out For Possible Changes In Energy Drink Industry
• Smith & Nephew Sued Over Painful Hip Replacement
• Terumo Targets Rivals Over Catheterization Device IP
• Novartis Kills $78M Noncompete Deal With Departing Chairman
• Calif. Class Certified In Arthritis Drink False Ad Suit
• Novartis Beats Osteoporosis Drug Injury Suit
• Things To Keep In Mind When Marking Your Pot
• J&J Vaginal Mesh Warnings Debated In Closing Args
• Valeant Pays $12M To Settle Wellbutrin Antitrust Claims
• Lawmakers Urge FDA To Stiffen Hydrocodone Controls
• Roche Escapes 40 Accutane MDL Suits Due To Lack Of Expert
• FDA Gets Dozens Of Complaints After Ranbaxy Recall
• Bristol-Myers Dodges 24 Wrongful Death Suits Over Toxins
• GCs Name 43 Best-Of-The-Best Attys
• Aussie Court Upholds Myriad's Breast Cancer Gene Patent
• No Touch Up On 'Natural' Beauty By Calif. Court
• Icahn Reveals 13% Herbalife Stake, Heats Up Ackman Feud
• Sandoz, Intas Can't Ditch Merck's Suit Over Generic Emend
• GCs Name Cream Of The Crop Litigators
• GSK Wants Out Of HIV Drug Kickback Suit
• Divergent Approaches To Claim Construction
• Fed. Circ. Backs AstraZeneca Win In Seroquel XR Patent Row
• Office Campus Plans In $4B SF Project Get Panel's OK
• Record $688M Merck Settlement May Not Be Contagious
• Impax's Appeal Too Late In Amrix Case, Fed. Circ. Says
• Generic Fentora Doesn't Violate Teva IP, Fed. Circ. Finds
• Covidien Sues Former Sales Rep For Jumping To Abbott
• Reckitt Kept Addiction Drugs Off Market: Antitrust Suit
• Cardinal Health Puts Up $2B For PE-Backed AssuraMed
• Senate's Pay-For-Delay Bill Would Weaken Drug Patents
• Merck To Pay $688M To Settle Investor Suits Over Vytorin
• DePuy Exec Says He Knew Of Safety Concerns For Hip Implant
• Walgreen Co. Can't Trademark Store-Brand Zyrtec
• Drug Industry Warns Against Medicare Part D Rebates
• Drug Cos. Faulted For Not Giving FDA Risky-Drug Info
• Judge Refuses To Step Down From NJ Accutane Cases
• Upsher, Forest Ink $11M Drug Price Inflation Settlement
• J&J Hit With $63M Verdict Over Children's Motrin Warning
• FDA Review Adds To Hospira's Regulatory Woes
• US Needs Drug Tracking System To Stop Counterfeits: Report
• Travelers' Suit Dropped From Neurontin MDL
• Panel Centers NECC Meningitis Cases In Mass., Not Minn.
• JPML Combines 9 Plavix Injury, FCA Actions In NJ
• A Food Industry Issue Menu For 2013: Part 1
• Enzo Again Hits Abbott With Patent Suit Over DNA Probes
• Generics Primed To Fight FDA On Labeling Flexibility
• BioZone Founder's $30M Suit Survives Forum Challenge
• Bristol-Myers Inks $440M Sales Deal With Reckitt Benckiser
• Primary Jurisdiction May Be Useful In Food Labeling Cases
• Union Sues FDA Demanding Full Report On St. Jude Probe
• States Ask 8th Circ. To Pause ACA Contraception Rule Appeal
• Mass Tort Reforms Prompt Fewer Filings, Philly Judge Reports
• WL Gore Fights Bard's Antitrust Claims In Stent Patent Case
• Fed. Circ. Affirms Boston Scientific's $42M Patent Win
• Gov't Can Depose Guidant Workers In $726M FCA Suit: Judge
• Illumina Sued For Rejecting Roche Bids That Topped $8B
• Judge Invalidates Bristol-Myers Patent For Hepatitis B Drug
• DePuy Hip Implant 'Poisoned' Dad, Daughter Testifies
• GSK Win In Paxil Suicide Case Upheld In NM Court
• 3rd Circ. Urged Not To Halt Antitrust Suit Over GSK Drug
• FDA Mulls Dramatic Shift In Generic-Drug Labeling Regs
• Fresenius Hid Cardiac Risks Of Dialysis Treatment, Suit Says
• Coke, GSK Dodge Cleanup Claims Over Ohio Landfill
• ABA Will Back Myriad's Gene Patents In Supreme Court
• Celgene Cancer Drug Makes Regulatory Strides In China, US
• U Of Illinois' Immunity Dooms Patent Challenge, Judge Says
• FDA Delays Novo Diabetes Drugs Over Heart Risks
• Drugmaker Paid Women Less Than Men, $100M Bias Suit Says
• Law360 Life Sciences Editorial Advisory Board
• GSK Lobs False Ad Suit At Teva Over Axed Wellbutrin Generic
• Ready Or Not, Final Compliance Guidelines Are Here
• XL Needn't Waive Deductible, Limits In Stryker Case: Judge
• Novartis Asks High Court To Restore Allergy Drug Patent
• No Space For Partner Egos In Law Firm Of The Future
• White House Says Sequester Threatens Drug Approvals
• Novartis Can't Shake $1M Aredia, Zometa Verdict In 4th Circ.
• AstraZeneca, Torrent Settle Time-Release Seroquel IP Row
• FDA Tells 2nd Circ. It's Not Bound To Feed Antibiotics Ban
• Drugmaker Titan Ordered To Shut Down U.S. Operations
• Par Pharma Sued Over Plans For Generic Constipation Drug
• AmerisourceBergen Sued Over CEO's Hefty Stock Payout
• 3SBio Valued At $350M In Go-Private Sale To CEO, PE Firm
• Shire Pays $48M To End Adderall Supply Suit
• A Defendant's Guide To Approaching Head Injury Cases
• SunPharma Strikes Out Again With $600M Taro Offer
• Catholic Leaders Reject ACA Contraceptive Compromise
• Pfizer Notes Doctor Decisions In Appeal Of $142M RICO Award
• FDA Pushes New Approach To Alzheimer's Drug Development
• DePuy Hip Implants Failed At Troubling Rate, Doc Testifies
• Docs Fear For Reputations Under Final Sunshine Rule
• Fed. Circ. Affirms Merck Win In Vytorin, Zetia Patent Case
• Ackman Has More Questions On Herbalife's Biz Model
• Breg Wins Bellwether Trial In Calif. Pain Pump Suits
• Teva Can't Swap Out Expert In HIV Drug Patent Trial
• AstraZeneca Ends Ky. AG's Seroquel Suit With $5.5M Deal
• Glenmark Sinks GSK Malaria Drug Patent In UK Court
• Human Genes Shouldn't Be Patented, DNA Pioneer Says
• CORRECTED: Jones Day Lands 2 M&A Pros For New Amsterdam Branch
• GSK Accused Of Ripping Off La. Medicaid Programs
• FDA's Label Directive Pumps Up Plaintiffs In Drug Suits
• House Bill Would End $29B Medical Device Excise Tax
• FDA Warns Clinics About New Bogus Batches Of Avastin
• Patent Re-Exams Can Rebut Willful Infringement, Cordis Says
• Warner Chilcott Faces Fresh Suit Over Doryx Generic Ploy
• DePuy Hip Deformity Rate Was Alarming, Expert Tells Jury
• Forest Labs Wants Class Nixed In $100M Gender Bias Suit
• Biogen Pays $3.25B For Stake In Elan's MS Drug
• Wyeth V. Weeks: Implications For Pharma Manufacturers
• Judge Denies Class Cert. In Antidepressant Marketing MDL
• Final Sunshine Rule Gives Doctors More Room To Experiment
• House OKs Bills To Boost Pediatric Training, Research
• FDA Aims To Invigorate Sluggish Drug-Labeling Overhaul
• Mylan Says Unnamed Inventor Invalidates Merck Vytorin Patent
• Stryker Wins $70M Jury Verdict In Zimmer Patent Suit
• Sens. Introduce Bill To Ban Pay-For-Delay Deals
• Med Journal Rule Harms Patient Privacy, Pharma Group Says
• FDA Generics Process Not Bound By 'Fairness,' DC Circ. Told
• Merck Loses Final Bellwether Trial In Fosamax MDL
• 1st Circ. Revives Investors' Feraheme Risks Class Action
• FDA Warns Novo On Drug Contamination Measures
• GSK Puts Up $900M To Boost Stake In Indian Unit
• Cadence Sues Sandoz Over Generic Ofirmev Plans
• Calif. Takes Stab At Its Own Essential Health Benefits
• Exploiting Calif.'s 'All Natural' Food Craze
• BioClinica Investor Wants $123M PE Takeover Put On Ice
• Birth Control Compromise Hard Pill For Insurers To Swallow
• Purdue Sues To Block Abuse-Proof OxyContin Generics
• Mylan Pushes Fed. Circ. To Revive 5 COPD Drug Patents
• New Drug Pathway Must Weigh Risk, Off-Label Use, FDA Hears
• Zicam Maker Pays $4.5M To Snuff Stock Fraud Suit
• Sanofi, BMS Sued By W.Va. AG Over Plavix Marketing
• GOP Threatens To Compel FDA Compounding Pharmacy Docs
• Challenging Ex Parte Communications With Physicians
• 2nd Circ. Won't Revive Elan, Pfizer Investor Row
• European Device Group Pushes For Changes To New EU Regs
• Roche's Real Aim In Recusal Bid May Be To Chasten Judge
• Obama's Compromise On Contraception Won't End Lawsuits
• Merck Claims Ky. AG Knows Nothing About Vioxx Prosecution
• J&J Unit Beats TCPA Junk Fax Class Action
• State Biosimilar Bills Pose New Threat To Budding Industry
• Feds Unveil ACA's Long-Delayed Doc Payment Sunshine Rule
• DePuy Hip Failure Caused By Metal Toxins, Jury Told
• US Tells High Court Myriad's Isolated DNA Can't Be Patented
• Shire Pays $57.5M To End ADHD Drug Marketing Probe
• Eisai Beats Whistleblower's Off-Label Marketing FCA Suit
• Pfizer Escapes Discrimination Suit Alleging Racism, Ageism
• A Prescription To Treat Reputational Ills In Pharma Cos.
• HHS Proposes Contraception Mandate Opt-Out
• J&J Ordered To Pay $181M In Attys' Fees In Risperdal Suit